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Usutu virus (USUV) is an African mosquito-borne 
flavivirus, member of the Japanese encephalitis 
antigenic group. This avian virus is transmitted by 
arthropod vectors (mainly mosquitoes of the Culex 
pipiens complex). It is well known that free-living 
birds, including migratory species, have the poten-
tial to disperse certain pathogenic microorganisms. 
Usutu virus has recently been introduced to Europe 
and is spreading through Austria, Hungary, Italy, 
Spain and Switzerland, causing disease in birds and 
humans. Like West Nile virus, USUV may become a 
resident pathogen in Europe and the consequences 
for public health should be considered. Many differ-
ent biotic and abiotic factors affect the survival of 
the virus in a new environment and influence the effi-
ciency of its geographical dispersal. In this article, 
we consider the possibility of including USUV infec-
tions among the vector-borne diseases to be moni-
tored in Europe.
Background
Usutu virus (USUV) is an African mosquito-borne virus 
of the family Flaviviridae, genus Flavivirus, belonging 
to the Japanese encephalitis serocomplex [1]. From an 
ancestral flavivirus with a bird/mosquito natural cycle 
evolved the different flaviviral species present today, 
such as USUV and West Nile virus (WNV) in Africa, Asia 
and Europe, Japanese encephalitis virus (JEV) in Asia, 
Murray Valley encephalitis virus in Australia and Saint 
Louis encephalitis virus in the American continent. 
USUV was originally isolated from a mosquito (Culex 
neavei) in 1959 in South Africa. Further USUV strains 
were detected from different bird and mosquito spe-
cies in Africa in subsequent years, but human dis-
ease (rash and fever) has only been reported once, in 
the Central African Republic [2,3]. In the past, USUV 
was not considered as a potential threat for humans 
because the virus had never been associated with 
severe or fatal diseases in animals or humans, and it 
had never before been observed outside tropical and 
subtropical Africa.
Avian, horse and vector surveillance
In the summer of 2001, USUV emerged in Austria, caus-
ing deaths in several species of resident birds, espe-
cially among birds of the order Passeriformes [4-6]. 
In the following years, the virus has been detected in 
dead birds and/or mosquitoes in several countries, 
including Hungary (2005) [7], Italy (2009) [8], Spain 
(2006 and 2009) [9,10] and Switzerland (2006) [11]. 
USUV infection has also been demonstrated serologi-
cally in wild bird hosts in the Czech Republic (2005) 
[12], England (2001–2002) [13], Germany (2007) [14], 
Italy (2007) [15], Poland (2006) [16], Spain (2003–2006) 
[17] and Switzerland (2006) [18] (Figure). The recurrence 
of the virus over several years in Austria (2001–2006) 
[19], Hungary (2003–2006) [7], Italy (2006–2008) [8] 
and Spain (2006, 2009) [9,10] suggests either frequent 
reintroduction of the virus or, more likely, persistence 
of the transmission in the affected areas, possibly 
through overwintering mosquitoes. Comparisons of 
pathologic alterations revealed similar lesions in birds 
infected in the Austrian, Hungarian, Italian and Swiss 
USUV outbreaks, and these findings were supported by 
partial nucleotide sequence analysis with >99% identity 
between the viruses which emerged in Vienna in 2001, 
in Budapest in 2005, and in Zurich and Milan in 2006. 
A one-time introduction of USUV from Africa to Europe 
(Vienna) is therefore highly likely, and this particular 
strain has since been spreading in Central Europe [11]. 
However, a two-year study carried out in 2008 to 2009 
in Italy to monitor the USUV circulation within the West 
Nile Disease (WND) national surveillance plan suggests 
a different scenario [20]. In that work, sentinel horses 
and chickens, wild birds and mosquitoes were sampled 
and tested for serological and virological evidence of 
USUV. Seroconversion in sentinel animals proved that 
the virus had circulated in Italy in these two years. In 
addition, the study demonstrated USUV infection in 
horses for first time in Europe. Sequence comparison 
of USUV detected from different species in different 
counties showed that two different strains of USUV 
are likely to have circulated in Italy between 2008 and 
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2009, and these strains have adapted to new hosts 
and vectors to become established in new areas.
Recent human cases and 
clinical characteristics
In the end of the summer 2009, the virus was associ-
ated with neurological disorders in two immunocompro-
mised patients (both had received blood transfusions) 
in Italy [21,22]. In addition, USUV was isolated from 
the blood obtained from one of these subjects during 
the acute stage of disease. The patients were detected 
concurrently with the active surveillance programme 
of blood and organ donations that the public health 
authority of the Emilia Romagna region had initiated in 
August 2008, based on several veterinary and entomo-
logical reports of WNV circulation in north-eastern Italy 
[23]. The two infections could be consistent with local 
transmission, either directly through a mosquito bite 
or indirectly through an infected donor. Both patients 
had in common that they were immunosuppressed and 
had received blood transfusions in the same period of 
time (August 2009). As transmission for WNV through 
blood products and transplantation has been docu-
mented [24,25], screening for WNV was performed of 
blood samples and organ donations from 15 June to 
31 October, with negative results. The two patients 
were the first human cases of USUV neuroinvasive 
illness described worldwide. The common clinical 
symptoms were persistent fever of 39.5 °C, headache 
and neurological disease (impaired neurological func-
tions). One patient developed a fulminant hepatitis, a 
pathology that had been described previously in rare 
cases of WNV infection [26,27]. In both patients, the 
clinical picture was similar, with a clear involvement 
of the central nervous system, resembling the related 
WNV neuroinvasive disease. Whether this new tropism 
was associated with new characteristics of the infect-
ing viruses, with a possible inoculation route through 
transfusion, and/or to the underlying diseases of the 
patients still remains unclear, but these findings rein-
force the need for further investigations. The partial 
sequences obtained from cerebrospinal fluid (CSF) 
and plasma samples of these patients were more than 
98% identical with the viruses that had emerged in 
Vienna and Budapest  (in 2001 and 2005, respectively) 
[21,22]. In a recent phylogenetic study of sequences of 
USUV strains obtained in Italy in 2009 from mosqui-
toes, birds and humans, the sequences obtained from 
human hosts clustered with the sequences obtained 
from birds, which would indicate an endemic distribu-
tion of USUV in Europe [20].
Diagnostics
Clinical suspicion of USUV infection requires labora-
tory confirmation. Within laboratory methods, we can 
distinguish between direct methods (detecting the 
virus by cell culture or genomic amplification) and 
indirect methods (detect the antibody response to the 
infection). Serological diagnosis of USUV infections in 
humans will require an approach similar to the one used 
for WNV. Although there is a lack of experience about 
USUV infection in humans, it is assumed that its incu-
bation period will be two to 14 days, that USUV will be 
detectable in CSF and serum in the acute stage of the 
disease, and that IgM antibodies will appear five days 
after onset of fever, in analogy to the current knowl-
edge about the pathogenesis of WNV-related illness 
in humans. Antibodies may persist in serum for many 
months after infection [28]. Diagnosis of USUV will not 
be easy, particularly in areas where circulation along 
with others cross-reacting flaviviruses occur. That is 
the case for WNV and tick-borne encephalitis virus in 
several European countries [29]. Until more specific 
diagnostic methods are developed and made avail-
able for diagnostic laboratories, antibody detection 
could be carried out using cross-reacting ELISA meth-
ods designed for WNV diagnosis.  It is also expected 
that cross-reactivity will be higher for IgG than for 
IgM detection; consequently, development of tests 
for USUV-specific IgM is needed more urgently. As an 
already available alternative, acute and convalescent 
sera should be tested for seroconversion of IgG anti-
bodies using in-house or commercial ELISA tests based 
on WNV antigens. Cross-reactions can be resolved by 
parallel titrations against various flaviviruses in assays 
for neutralising antibodies, which are more specific 
Figure
Diagnostic capacities for Usutu virus in European 
countries in the ENIVD network and detection of the 
virus in mosquitoes, birds, horses and/or humans 
ENIVD: European Network for Diagnostics of Imported Viral 
Diseases.
Colour code indicates diagnostic capacities: direct methods detect 
the virus by cell culture or genomic amplification, indirect methods 
detect the antibody response to the infection. 
Animal symbols indicate detection of Usutu virus in these species: 
geographical distribution is indicated either by virus detection 
(species in white) or by evidence of neutralising antibodies (dark 
grey).





than ELISAs but can be performed only in specialised 
laboratories that can handle hazardous viruses [30].
The possibility of USUV to infect and cause severe neu-
rological syndromes in humans makes it necessary to 
develop new affordable and rapid molecular methods 
for its detection. Recently, a specific real-time RT-PCR 
assay has been developed to identify USUV in human 
plasma, serum and CSF samples. This technique has 
allowed the detection of USUV in three CSF specimens 
that were collected in the summers of 2008 and 2009 
from 44 patients with suspected meningoencephalitis 
and were negative for WNV [31]. However, serological 
testing is still needed and important to identify infec-
tion after the viraemic stage. In Europe, most of the 
countries are prepared for detecting USUV genome in 
human or bird samples (Figure), generally using cross-
reactive or generic methods for detecting flaviviruses. 
More specific techniques are required, especially for 
those countries with direct evidence for WNV and/or 
USUV circulation (Austria, Belarus, Bulgaria, Czech 
Republic, France, Hungary, Italy, Moldova, Portugal, 
Romania, Russia, Slovakia, Spain and Ukraine) [32], 
and new methods are being designed to identify and 
distinguish USUV from other arboviruses, particularly 
from members of the JEV group that have been circulat-
ing in Europe [31,33]. In fact, a false-positive result of a 
WNV RT-PCR was reported in Italy in 2009 in a patient 
with viraemia caused by USUV [23].
Surveillance and control
The number of recent notifications of mosquito-borne 
diseases in the European Union in 2010 is a reason 
for concern. These events involved different types of 
pathogens like WNV, USUV, dengue virus, chikungunya 
virus and Plasmodium sp, some of which are consid-
ered typical for tropical areas. This current situation 
triggered a request from the European Commission 
for a risk assessment [34]. The overall objective of 
this consultation was to acquire a comprehensive 
understanding of the transmission potential for mos-
quito-borne diseases in Europe in order to propose 
recommendations for preparedness actions. The final 
conclusion was to develop a tool for decision making in 
WNV infection preparedness and control, which would 
guide countries through the complexities of respond-
ing to any alerts or outbreaks of this disease.
In Europe, WNV re-emerged in Romania, where it was 
first associated to neurological disease [35]. Since 
then, the virus has been detected with increasing 
activity in several European countries [36], includ-
ing Italy, where it was circulating at least in 2008 and 
2009, with eight and 16 human cases, respectively, of 
West Nile neuroinvasive disease [37]. Because of WNV 
circulation in Italy with neuroinvasive cases in humans 
and horses [38,39], a regional surveillance plan was 
implemented starting from 2008 [40]. Thanks to, these 
WNV surveillance activities antibodies against WNV 
and USUV were detected in Italy in 2009 in sentinel 
animals (horses and chickens), wild birds and provided 
evidence of cocirculation of WNV and USUV in mosqui-
toes and birds in the same area [20,41,42].
That five human USUV infections have recently been 
detected in areas where an effective surveillance for 
WNV exists, suggest that this disease may also be 
under-recognised in some other areas where the sur-
veillance for WNV is lacking or poorly implemented. 
Both viruses seem to be able to cause neurological 
disease in humans under certain circumstances. The 
emergence of USUV in Europe, even if not presently 
considered a major threat warrants the enhancement of 
surveillance plans for neuroinvasive illness during the 
summer season, corresponding to the peak of activity 
of potential vectors. The extension of surveillance to 
flaviviruses other than WNV will require new diagnostic 
procedures and the development of more specific sero-
logical tests that can be used in the field [42]. As WNV 
and USUV viruses share many eco-epidemiological 
and virological characteristics, WNV surveillance pro-
grammes could be easily adapted to survey also USUV 
in birds, horses, mosquitoes and human samples. 
This approach should be based on the development 
of adequate and standardised differential laboratory 
diagnosis using validated methods (serological and 
molecular) enabling the differential detection of WNV 
and USUV infections, especially in those countries with 
demonstrated co-circulation of both viruses (at least 
Austria, Hungary, Italy, and Spain). A specific real-
time RT-PCR assay to identify USUV in human plasma, 
serum, and CSF that has been developed [31] is very 
helpful for donor screening and diagnostics. Some of 
the molecular techniques designed to detect WNV can 
also amplify the signal for USUV due to false positive 
results by lack of specificity in the technique.
A surveillance programme for USUV in Europe could 
be very similar to national surveillance systems for 
WNV that are already implemented in some countries 
in Europe. In fact, in those European countries which 
have implemented a national WNV surveillance plan, 
this could be used in parallel for USUV surveillance. 
These programmes consist of human, veterinary and 
entomological surveillance. The objective of passive 
and active human surveillance systems would be the 
early detection of infection in humans. This activity 
should be performed by serology and/or detection 
of the viral genome in blood and cerebrospinal fluid 
from all suspected cases suffering from acute menin-
goencephalitis. In this regard, it would be important 
to raise the awareness of clinicians for this emerging 
disease, which may improve the sensitivity of the sur-
veillance system. Since the diagnosis of encephalitis 
is of general importance, the inclusion of USUV diag-
nostics for differential diagnosis in cases of unknown 
origin should be considered for extended screening 
of aetiologies. Key requirements for a possible future 
surveillance study at European level have already been 
suggested [30]. Animal surveillance should be per-
formed on the basis of passive and active surveillance 
of horses and non-migratory wild birds. Entomological 
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surveillance should be based on the weekly to monthly 
(frequency depending on local resources) collection of 
mosquitoes in fixed stations and at sites where USUV 
activity has been demonstrated ascertained in birds, 
humans or horses.
As suggested by Chvala et al. [5], mosquito monitor-
ing and screening of wild birds are suitable to detect 
USUV circulation and could replace surveillance of 
dead birds when bird mortality drops because of herd 
immunity. Although virological surveillance (with 
molecular techniques) may be preferable over sero-
logical monitoring because it avoids cross-reactions 
with other flaviviruses, they are impeded by short-
lived viraemia, when serology is still possible due to 
long-lasting serum antibodies. Sera reacting to both 
WNV and USUV were detected in other studies using 
tests with low specificity such as haemagglutination 
inhibition [19] or ELISA [15]. Plaque reduction neutrali-
sation has to be performed to confirm positive sera, 
but this test is complex, costly, time-consuming and 
not accessible for laboratories lacking high biocon-
tainment facilities.
As for WNV, surveillance of wild birds and vectors will 
be used in the coming years to forecast the spread 
of USUV. The information gathered will be used to 
develop actions to prevent virus transmission, such as 
vector monitoring and control, information campaigns 
to improve personal protection, and screening tests for 
donor blood, tissue and organs.
Conclusions
In Europe the risk exists that potential emerging infec-
tious diseases, such as those caused by WNV or USUV, 
will not be recognised in time by existing surveillance 
infrastructures of the various European countries [43]. 
As treatments for USUV and WNV are not available, 
there is a need to strengthen surveillance. Circulation 
of USUV in Austria, Hungary, Italy and Spain dur-
ing consecutive years and seroconversions reported 
recently in sentinel animals and detection of virus in 
wild birds in Italy, show that these territories are suit-
able to support USUV circulation between vectors and 
vertebrate hosts, as well as overwintering, enabling the 
establishment of endemic cycles. This indicates a need 
to organise standard surveillance measures and early 
warning systems to detect WNV and USUV activity, 
and to assess the risk for public health. Establishing 
a European surveillance system by grouping the exist-
ing resources and introducing a standardised reporting 
and diagnostic system is essential for future prepared-
ness and response. This surveillance system should be 
sensitive and able to detect USUV and WNV circulation 
at an early stage. A multidisciplinary approach should 
be considered when evaluating the risk of USUV and 
WNV transmission, and the contribution of the differ-
ent components (mosquitoes, birds, horses, humans) 
should be carefully assessed.
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